Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis

PURPOSE: Two randomized trials published in 2001 provided level 1 evidence for the use of cytoreductive nephrectomy (CyNx) for the treatment of metastatic renal cell carcinoma (mRCC). However, the regulatory approval of vascular endothelial growth factor tyrosine kinase inhibitors (VEGFR-TKI) in 200...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:World J Urol
Autors principals: Tsao, Che-kai, Small, Alexander C., Kates, Max, Moshier, Erin L., Wisnivesky, Juan P., Gartrell, Benjamin A., Sonpavde, Guru, Godbold, James H., Palese, Michael A., Hall, Simon J., Oh, William K., Galsky, Matthew D.
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4744480/
https://ncbi.nlm.nih.gov/pubmed/23223962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00345-012-1001-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars